VASC 27.00 Vascular Solutions $VASC Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
VASC 27.00 Vascular Solutions $VASC Hit a 52 week high of 28.50 Closing the day 09:45 at 27.00 -3.50 -11.48% With a day low of 26.02 and a total volume of 93,017.

VASC Recent Posts: http://investorshangout.com/Vascular-Solutions-VASC-55784/

VASC Vascular Solutions Recent Headline News

INVESTOR ALERT: Investigation of Vascular Solutions, Inc. Announced by Glancy Binkow & Goldberg LLP
Business Wire - 2 hrs 4 mins ago
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Vascular Solutions, Inc. ("Vascular Solutions" or the "Company" (NASDAQ:VASC) concerning possible violations of federal securities laws. The investigation is focused on certain statements issued by Vascular Solutions concerning the Company's operations and financial prospects.
VASC: 23.49 (-7.01)

Nasdaq stocks posting largest percentage decreases
AP - 2 hrs 20 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
EGLT: 6.42 (-0.42), VCYT: 6.78 (-0.68), ANY: 9.24 (-0.26), ALNY: 91.25 (-8.08), RTRX: 10.00 (-1.62), VASC: 23.49 (-7.01), DGLY: 11.55 (-1.67)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 2 hrs 51 mins ago

ZIOP: 3.73 (+0.44), BSPM: 1.33 (-0.40), BDR: 1.74 (+0.44), ZAZA: 3.20 (-0.35), ACY: 8.45 (-2.90), NBS: 6.24 (+0.85), SYRX: 1.30 (-1.00), IAG: 2.11 (+0.37), THTI: 1.28 (-0.41), BITA: 91.32 (+12.03), VRTB: 4.91 (+0.35), OPTT: 1.18 (+0.15), INVT: 0.79 (-0.43), GERN: 2.76 (+0.45), VASC: 23.49 (-7.01), LOCM: 1.40 (+0.09), CTHR: 1.73 (-0.89), MOV: 27.26 (-11.25), IFON: 1.34 (-0.53), SVM: 1.36 (+0.20)

EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Class Action Claims Against Vascular Solutions, Inc.
Business Wire - Fri Nov 14, 10:49AM CST
The Rosen Law Firm announces that it is investigating potential securities claims against Vascular Solutions, Inc. (NASDAQ:VASC) resulting from allegations that the Company may have issued materially misleading business information to the investing public.
VASC: 23.49 (-7.01)

Uptrend Call Working As Vascular Solutions Stock Rises 25.0% (VASC)
Comtex SmarTrend(R) - Fri Nov 14, 9:41AM CST
SmarTrend identified an Uptrend for Vascular Solutions (NASDAQ:VASC) on June 6th, 2014 at $21.35. In approximately 5 months, Vascular Solutions has returned 25.02% as of today's recent price of $26.68.
VASC: 23.49 (-7.01)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vascular Solutions, Inc. - VASC
PR Newswire - Fri Nov 14, 9:40AM CST
Pomerantz LLP is investigating claims on behalf of investors of Vascular Solutions, Inc. ("Vascular" or the "Company" (NASDAQ: VASC). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
VASC: 23.49 (-7.01)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vascular Solutions Inc.
PR Newswire - Fri Nov 14, 9:39AM CST
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Vascular Solutions ("Vascular Solutions" or the "Company" (NasdaqGS: VASC -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
VASC: 23.49 (-7.01)

Vascular Solutions' board authorises USD20m share repurchase programme
M2 - Fri Nov 14, 6:19AM CST
The board of directors of Vascular Solutions (NasdaqGS:VASC), a medical device company, on Thursday approved its share repurchase plan for up to USD20m of its common stock.
VASC: 23.49 (-7.01)


Federal grand jury indicts Vascular Solutions CEO
Star Tribune - Thu Nov 13, 9:21PM CST
MINNEAPOLIS (AP) — A federal grand jury in Texas indicted the CEO of Minnesota-based medical device maker Vascular Solutions Inc. Thursday on charges he conspired to sell a varicose-vein treatment device for unapproved uses.
VASC: 23.49 (-7.01)

Vascular Solutions indicted for off-label promotion
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 4:23PM CST

VASC: 23.49 (-7.01)

Vascular Solutions Announces $20 Million Share Repurchase Plan
GlobeNewswire - Thu Nov 13, 3:09PM CST
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that its Board of Directors has authorized a share repurchase plan for up to $20 million of Vascular Solutions' common stock.
VASC: 23.49 (-7.01)

Statement of Vascular Solutions on Grand Jury Indictment
GlobeNewswire - Thu Nov 13, 3:09PM CST
In response to an indictment returned today by a federal grand jury in the Western District of Texas, Vascular Solutions, Inc. (Nasdaq:VASC) issued the following statement:
VASC: 23.49 (-7.01)

Vascular Solutions Has Returned 40.6% Since SmarTrend Recommendation (VASC)
Comtex SmarTrend(R) - Fri Nov 07, 9:11AM CST
SmarTrend identified an Uptrend for Vascular Solutions (NASDAQ:VASC) on June 6th, 2014 at $21.35. In approximately 5 months, Vascular Solutions has returned 40.59% as of today's recent price of $30.01.
VASC: 23.49 (-7.01)

Vascular Solutions to Present at the Canaccord Genuity Medical Technology and Diagnostics Forum
GlobeNewswire - Thu Nov 06, 3:20PM CST
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that the Company is scheduled to present at the Canaccord Genuity Medical Technology and Diagnostics Forum in New York City on Thursday, November 20th at 2:30pm (EST).
VASC: 23.49 (-7.01)

Vascular Solutions to Present at the 2014 Stifel Nicolaus Healthcare Conference
GlobeNewswire - Tue Nov 04, 3:05PM CST
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that the Company is scheduled to present at the 2014 Stifel Nicolaus Healthcare Conference in New York City on Tuesday, November 18th at 4:45pm (EST).
VASC: 23.49 (-7.01)

Vascular Solutions to Distribute PolarCath(TM) Peripheral Dilatation System
GlobeNewswire - Tue Nov 04, 8:00AM CST
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that it has entered into an agreement with NuCryo Vascular LLC under which Vascular Solutions will serve as exclusive distributor of the PolarCath Peripheral Dilatation System in the United States.
VASC: 23.49 (-7.01)

Vascular Solutions Shares Up 36.6% Since SmarTrend's Buy Recommendation (VASC)
Comtex SmarTrend(R) - Thu Oct 30, 4:39PM CDT
SmarTrend identified an Uptrend for Vascular Solutions (NASDAQ:VASC) on June 6th, 2014 at $21.35. In approximately 5 months, Vascular Solutions has returned 36.61% as of today's recent price of $29.16.
VASC: 23.49 (-7.01)

Strong And Under The Radar Today: Vascular Solutions (VASC)
at The Street - Thu Oct 30, 9:11AM CDT
Trade-Ideas LLC identified Vascular Solutions (VASC) as a strong and under the radar candidate
VASC: 23.49 (-7.01)

Vascular Solutions Up 28.6% Since SmarTrend Uptrend Call (VASC)
Comtex SmarTrend(R) - Thu Oct 23, 11:01AM CDT
SmarTrend identified an Uptrend for Vascular Solutions (NASDAQ:VASC) on June 6th, 2014 at $21.35. In approximately 5 months, Vascular Solutions has returned 28.62% as of today's recent price of $27.46.
VASC: 23.49 (-7.01)

Vascular Solutions posts 3Q profit
Automated Insights - Tue Oct 21, 4:31PM CDT
MINNEAPOLIS (AP) _ Vascular Solutions Inc. (VASC) on Tuesday reported profit of $2.6 million in its third quarter.
VASC: 23.49 (-7.01)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Agroz's Big Leap: New Supply Deal in Malaysia

Updated Category News Views 3

Agroz Inc. Executes a Game-Changing Deal If anyone thought the ag tech players were sitting idle, think again. Agroz Inc., noted for their innovative controlled-environment agriculture, just inked a pivotal deal with Harvest Hive in Malaysia. It's not just a nod to expansion—it's a strategic leap into the big leagues. Picture this: Harvest Hive's sprawling 500-acre farm...

Continue Reading
RARE Foundation Rebrands, Focus Still Strong

Updated Category News Views 3

Unveiling the RARE Foundation's New Identity In the stock market, you ride waves of change, and let me tell you, it ain't just stocks and bonds that change names and faces. Case in point: The EveryLife Foundation for Rare Diseases has spiffed up as the RARE Foundation. New name, new logo, the whole enchilada. This isn't just a cosmetic touch-up, though. It's about...

Continue Reading
Cove Capital Secures $9.96M for Debt-Free Logistics DST

Updated Category News Views 3

Unpacking Cove Capital's Latest Victory Cove Capital Investments has pulled off another coup, raising a hefty $9,964,510 for its Cove Essential Net Lease Industrial 108 DST. It's a Regulation D, Rule 506(c) offering, now fully subscribed, spotlighting a debt-free investment ethos and a rock-solid logistics site in Anchorage, Alaska. Strategic Facility Anchoring Investment...

Continue Reading
CUBEX Lights Up Veterinary Care with Mini Essential

Updated Category News Views 5

Inventory Woes? Meet Mini Essential If you’ve ever worked in or around veterinary hospitals, you know the old-school headaches of managing controlled substances. Picture this: piles of paper logs, end-of-shift recounting, and inevitable discrepancies that rear their ugly heads long after closing time. Enter CUBEX, shaking things up with their latest launch, Mini...

Continue Reading
MCatalysis Secures $5M to Disrupt Fuel Cost Dynamics

Updated Category News Views 3

Funding Fuels Innovation MCatalysis has just secured a hefty $5 million in seed funding to throw down with the big dogs in energy production. This isn't your regular backyard science project; this company is serious about changing the game with a tech-driven approach that could undercut current fuel prices. HL Energy Ventures and Oxford Science Enterprises are backing...

Continue Reading
Midlife ADHD in Women: New Challenges and Solutions

Updated Category News Views 5

ADHD Evolution in Women's Midlife They say change is the only constant, and boy, does that ring true for women navigating the turbulent seas of ADHD as they hit 40 and beyond. According to Germaine Swanson, the ADHD landscape changes dramatically in midlife, especially for women. We're talking about a mix of hormonal shifts, increasing life demands, and changes in brain...

Continue Reading
Tampa General’s Innovation Excellence Earns No. 20 Spot

Updated Category News Views 7

A Bold Leap into Innovation at Tampa General There's a heck of a lot going on down in Tampa that's worth more than just a golf clap. Tampa General Hospital (TGH) just snagged the 20th spot on Fast Company's Best Workplaces for Innovators list, and let me tell you, that’s no small feat amidst the heavy hitters in verticals like biotech and consumer goods. It takes guts...

Continue Reading
Give Lively & Change Simplify CA Nonprofit Compliance

Updated Category News Views 1

A Fresh Wind Blowing for California Nonprofits So, here's a twist in the nonprofit world that's stirring the pot just right. Give Lively and Change have partnered up to tackle the thorny issue of regulatory compliance in California. It's a big win for the nonprofits looking to keep fundraising through Give Lively without getting tangled in the bureaucratic web spun up by...

Continue Reading
Veho's Role in Redefining Beauty E-Commerce Delivery

Updated Category News Views 2

Veho Grabs Headlines with BeautyMatter Awards Nod Here's something a bit off the beaten path: Veho's been tapping into new wells of opportunity in the e-commerce sector, and their latest accolade demonstrates just that. Named a finalist in the 2026 BeautyMatter Awards under the Logistics category, they're making noise in all the right circles. Beyond Boxes: Transforming...

Continue Reading
RevSystems Joins Elite OpenAI Partner Network

Updated Category News Views 3

RevSystems Inks Deal with OpenAI Partner Network In the latest shuffle of the AI advisory deck, RevSystems just found itself elbowing into the exclusive OpenAI Partner Network. Based out of New York, RevSystems has carved a niche by spinning tech wizardry into tangible business results. Their new status as an OpenAI Select Partner puts them on a playing field where AI...

Continue Reading

Top 5 Most Recently Viewed Articles

Natural Diamonds Resilient Amid Market Shifts and Trends

Updated Category News Views 679

The Strength of Natural Diamonds in Today's Market As we enter a new year, the natural diamond market has shown a robust performance, providing encouraging signs of stability, strength, and growth. Jewelers have reported solid year-end results, showcasing steady or improved sales levels compared to previous periods. This positive trend reinforces the perception of natural...

Continue Reading
Bicara Therapeutics' Plans for Public Offering Showcase Growth

Updated Category News Views 183

Overview of Bicara Therapeutics' Initial Public Offering Bicara Therapeutics Inc. (NASDAQ: BCAX), an innovative biopharmaceutical company currently in the clinical stage, has just taken an exciting step forward. They've announced the pricing for their initial public offering (IPO), which includes 17,500,000 shares of common stock, each priced at a competitive $18.00. This...

Continue Reading
Class Action Alert for Semtech Corporation Investors

Updated Category News Views 107

Legal Update for Semtech Corporation Shareholders The Gross Law Firm has released an important notice specifically for shareholders of Semtech Corporation (NASDAQ: SMTC). This notice comes in light of a class action lawsuit that has been filed, and it outlines essential details regarding the lawsuit and actions that shareholders can take to safeguard their rights....

Continue Reading
Critical Insights on the Beyond Meat Securities Investigation

Updated Category News Views 241

Understanding the Investigation into Beyond Meat Beyond Meat, Inc. (NASDAQ: BYND), renowned for its innovative plant-based meat alternatives, is currently under scrutiny regarding potential violations of federal securities laws. This investigation, announced by a leading securities law firm, raises concerns for investors who may have suffered losses due to possible...

Continue Reading
Immunic Navigates Investor Events As Trials Advance

Updated Category News Views 2

Braving the Investor Circuit Immunic's ready to make some moves this July—this crew's diving headfirst into a trio of investor conferences. They're not just chitchatting; they’re taking one-on-one meetings, holding fireside chats. What’s the big draw? Their brainchild, vidofludimus calcium (IMU-838), which is knee-deep in phase 3 trials for relapsing multiple...

Continue Reading